Sichuan University

This study tests a new approach for people with stage II to III non-small cell lung cancer that can be surgically removed. Before surgery, participants receive low-dose radiation, a precise high-dose radiation treatment (SBRT), and a combination of immunotherapy (tislelizumab) an…

This study tests whether intensive nutritional support can improve outcomes for people with locally advanced esophageal cancer that cannot be surgically removed yet. Participants receive standard chemotherapy plus immunotherapy, and are randomly assigned to either intensive nutri…

This study tests a new treatment for people with a specific type of advanced small cell lung cancer (SLFN-11 positive). It combines low-dose radiation, chemotherapy, and two drugs (sugemalimab and olaparib) to see if it is safe and effective. About 45 adults who have not had prio…

This study tests whether adding low-dose radiation to a combination of immunotherapy (sintilimab) and chemotherapy can shrink tumors better than the drug combo alone in people with advanced squamous cell lung cancer. About 114 participants will be randomly assigned to one of two …

This study tests a new approach for people with advanced esophageal cancer that cannot be removed by surgery. It combines a cancer-killing virus with chemotherapy and an immunotherapy drug. The goal is to shrink tumors enough to allow surgery and improve long-term outcomes. About…

This study is for people with extensive-stage small cell lung cancer, a fast-growing type of lung cancer that has spread. The trial tests whether adding a low dose of radiation to a combination of immunotherapy (adebrelimab) and chemotherapy can help patients live longer. About 2…

This early-phase study tests a new treatment approach for people with large solid tumors that have not responded to standard therapy. The treatment combines low-dose radiation, precise high-dose radiation, and an immunotherapy drug called tislelizumab. The main goal is to check s…

This study tests a new drug called sunvozertinib combined with chemotherapy in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard targeted therapy. About 40 adults will receive the combination to …